Avid Bioservices Inc (CDMO)

[entdoc]

4ourRetirement, a bit of a reach on that theory, but it might indeed smooth the red tape involved in moving right into adding Bavi if 1st line treatment is failing. interesting idea. Bavi's true potential is not in failed first line treatment, but in early diagnosis and treatment. bulky solid tumors are simply not the reasonable or logical application...unless Bavi is bearing a cytotoxic warhead.